Board meeting on 30 Oct 2026 to consider Q2 and H1 FY27 results

Results View source PDF Explain this filing

AJANTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹3330.00

prior close

₹3339.50

announcement price

In-mkt

timing

Nifty Midcap 150market-0.3%+1.2% vs market

Pharmaceuticals peers, median of 172sector-0.6%+1.5% vs sector

On the reaction day the stock moved 1.2 pts more than Nifty Midcap 150 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

+0.2

15m

+0.1

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9-0.3+1.2-0.6+1.5

Next day

-0.3-0.4+0.1-0.7+0.4

-1.0-1.5+0.5-1.9+0.9

-2.1-2.8+0.7-3.5+1.4

-1.7-3.6+1.9-4.4+2.7

-1.4-5.6+4.3-6.1+4.7

+0.2-3.7+3.9-2.9+3.0

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ajanta Pharma has informed BSE that its Board of Directors will meet on 30 October 2026 to consider and approve the unaudited consolidated and standalone financial results for the second quarter and half year ended 30 September 2026.

Likely market impact

Routine advance notice; investors should watch for the Q2 and H1 FY27 results announcement after the board meeting.